Scancell Valuation Multiples

Scancell Overview

About Scancell

Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.

Founded

2008

HQ

Employees

60

Website

scancell.co.uk

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $2M

EBITDA: ($17M)

EV

$196M

Valuation Multiples

Multiples.vc

Start free trial

Scancell Financials

Scancell reported last 12-month revenue of $2M and negative EBITDA of ($17M).

In the same LTM period, Scancell generated $2M in gross profit, ($17M) in EBITDA losses, and had net loss of ($10M).

Scancell P&L

In the most recent fiscal year, Scancell reported revenue of $6M and EBITDA of ($17M).

Scancell expects next 12-month revenue of XXX and NTM EBITDA of XXX

Scancell Stock Performance

Scancell has current market cap of $186M, and enterprise value of $196M.

Scancell's stock price is $0.18.

Scancell Valuation Multiples

Scancell trades at 106.8x EV/Revenue multiple, and (11.5x) EV/EBITDA.

Scancell Financial Valuation Multiples

As of April 19, 2026, Scancell has market cap of $186M and EV of $196M.

Equity research analysts estimate Scancell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Scancell has a P/E ratio of (18.6x).

Scancell Margins & Growth Rates

Scancell's revenue in the last 12 month declined by (97%).

Scancell's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.4M for the same period.

Scancell's rule of 40 is (3784%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Scancell's rule of X is (3908%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Scancell Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Scancell M&A Activity

Scancell acquired XXX companies to date.

Last acquisition by Scancell was on XXXXXXXX, XXXXX. Scancell acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Scancell Investment Activity

Scancell invested in XXX companies to date.

Scancell made its latest investment on XXXXXXXX, XXXXX. Scancell invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).